Thomas Olencki

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul Nghiem, Shailender Bhatia, Evan J. Lipson et al. · New England Journal of Medicine · 2016 · 1.2K citations · Full text

Medicine, Dermatology, Oncology +17

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri, Susan Halabi, Ben L. Sanford et al. · Journal of Clinical Oncology · 2017 · 715 citations

Medicine, Oncology, Pharmacology +14

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal et al. · Journal of the National Comprehensive Cancer Network · 2017 · 580 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

John C. Morris, Antoinette R. Tan, Thomas Olencki et al. · PLoS ONE · 2014 · 483 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Guidelines of care for the management of basal cell carcinoma

Christopher K. Bichakjian, April W. Armstrong, Christian L. Baum et al. · Journal of the American Academy of Dermatology · 2018 · 480 citations · Full text

Medicine, Dermatology, Oncology +12